2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1141

Trajectories of Extensive Sitting and Associated Predictors in Persons at High Risk for Knee Osteoarthritis
Abstract Number: 444

Trajectories of Sport or Recreational Activities over Eight Years and Associated Factors in Persons at Risk for Knee Osteoarthritis
Abstract Number: 1705

Trajectory Analysis of Combined Disease Activity and Physical Component Summary Scale in an Inception Cohort of Adults with Systemic Lupus Erythematosus: Latent Classes Inform Different Patterns
Abstract Number: 998

Transcription Factor Fli-1 Impacts Renal IL-17 Expression in Adult MRL/Lpr Mouse Despite Similar Interstitial Immune Cell Infiltration into the Kidney
Abstract Number: 1977

Transcriptional Perturbation of RA-Risk Enhancer By CRISPR-DEADCAS9 Regulates LONG Range GENE Targets
Abstract Number: 929

Transcriptional Profiling of the Subcutaneous Rheumatoid Nodule: An Insight into Pathogenic Mechanisms and Cellular Content
Abstract Number: 1966

Transcriptome and Methylome Integrative Molecular Analysis Uncovers a New Systemic Autoimmune Disease Classification
Abstract Number: 2280

Transcriptomic Analysis of Hidradenitis Suppurativa Skin Demonstrates Dysregulation of Antimicrobial Proteins and Inflammatory Pathways
Abstract Number: L19

Transcutaneous Electrical Nerve Stimulation (TENS) Reduces Pain and Fatigue and Improves Disease Impact in Women with Fibromyalgia: A Randomized Controlled Trial
Abstract Number: 976

Transitioning from Paediatric to Adult Health Services: Development of an Integrated Programme Incorporating Patient and Provider Values
Abstract Number: 2076

Transmembrane TNF (tmTNF) Transgenic Mice Exhibit Enlarged Lymph Nodes and Elevated Numbers of High Endothelial Cells Associated with Increased Lymphocyte Recruitment
Abstract Number: 2491

Treat-to-Target (T2T) Is Not Enough: Identify Factors Leading to a Mismatch between T2T and HAQ Among RA Patients through Data Mining from Smart System of Disease Management (SSDM)
Abstract Number: 978

Treat-to-Target Study for Improved Outcome in Polyarticular Juvenile Idiopathic Arthritis
Abstract Number: 803

Treating Interstitial Lung Disease and Skin Involvement in Systemic Sclerosis with Oral Versus Intravenous Cyclophosphamide: Preliminary Efficacy and Safety Data from 2 Randomized Clinical Trials and 1 Registry
Abstract Number: 1923

Treating Rheumatoid Arthritis to Target: Is Low Disease Activity Good Enough?

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].